ACRV logo

ACRV
ACRIVON THERAPEUTICS INC

1,153
Mkt Cap
$76.62M
Volume
720,357.00
52W High
$3.56
52W Low
$1.05
PE Ratio
-0.89
ACRV Fundamentals
Price
$1.79
Prev Close
$1.79
Open
$1.88
50D MA
$1.72
Beta
1.80
Avg. Volume
840,980.91
EPS (Annual)
-$2.02
P/B
0.73
Rev/Employee
$0.00
$23.07
Loading...
Loading...
News
all
press releases
Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday
Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
News Placeholder
More News
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, Marketbeat.com...
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Still a Buy?
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Should You Buy...
News Placeholder
Research Analysts Set Expectations for ACRV Q1 Earnings
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn...
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus...
News Placeholder
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday
Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-acrivon-therapeutics-inc-stock...
News Placeholder
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
News Placeholder
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer...
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 30th, there was short interest totaling 2,024,627...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available